These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36267268)

  • 21. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
    Al-Samkari H; Nagalla S
    Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: a clinical study].
    Dong F; Ma N; Chang S; Yang H; Gao M; Liu Q; Sun X; Liang M; Sun R
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Dec; 32(12):1445-1449. PubMed ID: 33541495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avatrombopag for the treatment of immune thrombocytopenia.
    Długosz-Danecka M; Zdziarska J; Jurczak W
    Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
    Olson SR; Koprowski S; Hum J; McCarty OJT; DeLoughery TG; Shatzel JJ
    Platelets; 2019; 30(6):796-798. PubMed ID: 30422039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
    Deng J; Hu H; Huang F; Huang C; Huang Q; Wang L; Wu A; Yang J; Qin D; Zou W; Wu J
    Front Pharmacol; 2021; 12():704093. PubMed ID: 34393785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
    Kuter DJ; Allen LF
    Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study.
    Ruan Y; Cao W; Luo T; Liu X; Liu Q; Xiao Y; Wu C; Xie D; Ren Y; Wu X; Feng X
    Front Pediatr; 2023; 11():1099372. PubMed ID: 36873638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avatrombopag: First Global Approval.
    Shirley M
    Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag.
    Van de Vondel S; Vandenbriele C; Gheysens G; Verhamme P; Janssens A
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100125. PubMed ID: 37065845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.
    Poordad F; Terrault NA; Alkhouri N; Tian W; Allen LF; Rabinovitz M
    Int J Hepatol; 2020; 2020():5421632. PubMed ID: 32047671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Al-Samkari H; Kolb-Sielecki J; Safina SZ; Xue X; Jamieson BD
    Lancet Haematol; 2022 Mar; 9(3):e179-e189. PubMed ID: 35240074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin levels in HIV-associated thrombocytopenia in children.
    Young G; Loechelt BJ; Rakusan TA; Nichol JL; Luban NL
    J Pediatr; 1998 Dec; 133(6):765-9. PubMed ID: 9842041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
    Cheloff AZ; Al-Samkari H
    J Blood Med; 2019; 10():313-321. PubMed ID: 31565009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study.
    Sheng XY; Liu ZY; Zhao J; Song L; Zhao WM; Zhao X; Cui YM
    Platelets; 2022 Nov; 33(8):1185-1191. PubMed ID: 35549802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia.
    Tu X; Xue A; Wu S; Jin M; Zhao P; Zhang H
    Front Pharmacol; 2021; 12():795884. PubMed ID: 35153753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.